Topic
The US market for health cover that employers buy for their staff, including plan design, broker distribution and annual renewal pricing.
Health Transformation Alliance data show 83% of Type 2 diabetes patients with no GLP-1 gains stayed on therapy, against 94% of responders. For employers setting 2027 terms, poor responders mostly do not leave the drug on their own.
Reality
HCCI claims data shows price increases drove 90% of the nearly 19% rise in per-person employer health spending between 2019 and 2023. That moves the cost question to price per service, and HCCI's chief executive points employers to direct provider negotiation.
Reality
Big Three PBM use among employers with fewer than 1,000 staff fell to 43.8% from 69.7% in a year, a purchaser coalition survey found. For calendar-year plans, federal rebate pass-through attaches at renewal from 2029, so the term signed in the 2027 cycle sets how long a plan waits for it.
Reality
Business Group on Health projects employer drug costs will rise 12% in 2026, faster than overall health costs, as GLP-1 and specialty use grows. For 2027 renewals, total pharmacy spend is a better test of a PBM than its rebate guarantee, though most PBM reports are not built to show it.
Reality
EBRI estimates employer health plans spend $12.7bn a year, about $101 a member, paying hospital outpatient rates for drugs that cost less in physician offices. The sum measures the full price gap between the two sites, so what an employer can recover depends on how many hospital infusions can safely move.
Reality
Sun Life US says high-dollar claims involving GLP-1 drugs rose 24% in a year and wants employers to treat coverage as cardiometabolic risk. Its data shows where catastrophic costs cluster, but any payoff from coverage depends on adherence, cost-sharing and tenure.
Reality
Mercer's survey of 1,800 employers has benefit costs per employee rising 8.2% in 2027, the steepest jump since 2003. Two-thirds of large companies plan to raise the employee premium share, and one independent medical practice was quoted 22.5%.
Reality
The $2.7bn headline price attaches to the $200m Series C. The Wall Street Journal reports the $400m tender offer priced at $2.5bn, and weighting the two puts the whole round nearer $2.57bn. None of the company's growth figures is audited.
Reality